No Detail Found!

Efficacy and Safety of Biologics and Immunosuppressants in Maintenance Therapy for Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Network Meta-Analysis

Author(s)
Liangdong Zhu Department of Respiratory and Critical Care Medicine, The First Hospital of Changsha, Hunan, China
Minfang Guo Department of Medical Oncology, The First Affiliated Hospital of Hunan Normal University, Hunan, China
Siyu Gan School of Clinical Medicine, Hunan University of Medicine, Hunan, China
Keyu Li Department of Respiratory and Critical Care Medicine, The First Hospital of Changsha, Hunan, China
Yong Fu Department of Nephrology and Rheumatology Immunology, The First Affiliated Hospital of Hunan University of Medicine, Hunan, China
Xia Chen Department of Nephrology and Rheumatology Immunology, The First Affiliated Hospital of Hunan University of Medicine, Hunan, China
Abstract
Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a potentially life-threatening systemic autoimmune disease. This study aims to compare the e ectiveness and safety of biologics and immunosuppressive agents in the maintenance treatment of AAV. A comprehensive search was conducted in Medline, PubMed, Embase, and the Cochrane Library databases to identify the relevant randomised controlled trials (RCTs). Nine RCTs involving 1,157 patients were included. For primary e cacy, rituximab had a lower relapse rate than azathioprine (AZA) and mycophenolate mofetil (MMF) (odds ratio (OR): 0.47, 95% con dence interval (CI): 0.26-0.84 and OR: 0.23, 95% CI: 0.08-0.68, respectively). Based on the result of the surface under the cumulative ranking curve (SUCRA), rituximab had the highest probability of reducing relapse (SUCRA = 86.6%), followed by cyclophosphamide (CYC), belimumab + AZA, methotrexate (MTX), AZA, and MMF. Regarding major relapse, rituximab also showed the highest probability (SUCRA = 93.6%). Concerning safety, there were no signi cant di erences in the incidence of SAEs and serious infection among the di erent medicines. According to the SUCRA, MMF had the lowest probability of SAEs and serious infection. In conclusion, rituximab may be a treatment method for e ectively reducing relapses in AAV patients during maintenance therapy among the medicines investigated. MMF has shown the lowest incidence of SAEs and serious infection.
Publication Details
Page(s) 636-641
Published Journal: Journal of the College of Physicians and Surgeons Pakistan, Volume: 35, Issue: 05, Year: 2025

Request the full text from PASTIC

Keywords
Meta-analysis, Rituximab, Immunosuppressant
References
Yates M,Watts RA,Bajema IM,Cid MC,Crestani B,Hauser T .2016 .ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann Rheum Dis, 10(9) : 1583-94.
Chevet B,Cornec D,Moura MC,Gall ECL,Fervenza FC,Warrington KJ .2023 .Diagnosing and treating ANCAassociated vasculitis: An updated review for clinical practice. Rheumatology, 10(5) : 1787-803.
Groh M,Pagnoux C,Baldini C,Bel E,Bottero P,Cottin V .2015 .Eosinophilic granulomatosis with polyangiitis (ChurgStrauss) (EGPA) consensus task force recommendations for evaluation and management. Eur J Intern Med, 04(7) : 545-3.
Robson JC,Grayson PC,Ponte C,Suppiah R,Craven A,Judge A .2022 .American College of Rheumatology/European Alliance of Associations for Rheumatology classi cation criteria for granulomatosis with polyangiitis. Ann Rheum Dis, 10(3) : 315-20.
Suppiah R,Robson JC,Grayson PC,Ponte C,Craven A,Khalid S .2022 .American college of rheumatology/European alliance of associations for rheumatology classi cation criteria for microscopic polyangiitis. Ann Rheum Dis, 10(3) : 321-6.
Frohnert PP,Sheps SG PP .1967 .Long-term follow-up study of periarteritis nodosa. Am J Med, 10(67) : 90144-1.
Hellmich B,Alamo BS,Schirmer JH,Berti A,Blockmans D,Cid MC .2024 .EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update. Ann Rheum Dis, 10(1) : 30-47.
Thietart S,Karras A,Augusto JF,Philipponnet C,Carron PL,Delbrel X .2022 .Evaluation of rituximab for induction and maintenance therapy in patients 75 years and older with antineutrophil cytoplasmic antibody-associated vasculitis. JAMA Netw Open, 20925(7) : .
Moura MC,Irazabal MV,Eirin A,Zand L,Sethi S,Borah BJ .2020 .E cacy of rituximab and plasma exchange in antineutrophil cytoplasmic antibody-associated vasculitis with severe kidney disease. J Am Soc Nephrol, 10(11) : 2688-704.
de Groot K,Harper L,Jayne DR,Gregorini G,Gross WL .2009 .Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibodyassociated vasculitis: A randomised trial. Ann Intern Med, 10(10) : 0003-80.
Villanueva FB,Loricera J,Rio VC,Selaya CC,Castaneda S,Blanco R .2023 .Intravenous immunoglobulin therapy in antineutrophil cytoplasmic antibody-associated vasculitis. Eur J Intern Med, 06 : 78-84.
Koike H,Nishi R,Ohyama K,Morozumi S,Kawagashira Y,Furukawa S .2022 .ANCA-associated vasculitic neuropathies: A review. Neurol Ther, 10(1) : 21-38.
Yates M,Watts R,Bajema I,Cid M,Crestani B,Hauser T .2017 .3(1):e000449. RMD open, 10 : .
Walsh M,Faurschou M,Berden A,Flossmann O,Bajema I,Hoglund P .2014 .Long-term follow-up of cyclophosphamide compared with azathioprine for initial maintenance therapy in ANCA-associated vasculitis. Clin J Am Soc Nephrol, 10(9) : 1571-6.
Terrier B,Pagnoux C,Perrodeau E,Karras A,Khouatra C,Aumaitre O .2018 .et a.l Long-term e cacy of remission-maintenance regimens for ANCA-associated vasculitidesA. nn Rheum Dis, 10(8) : 212768-6.
Smith RM,Jones RB,Specks U,Bond S,Nodale M,Al-Jayyousi R .2023 .Rituximab versus azathioprine for maintenance of remission for patients with ANCA-associated vasculitis and relapsing disease: An international randomised controlled trial. Ann Rheum Dis, 10(7) : 223559-44.
Pagnoux C,Mahr A,Hamidou MA,Ruivard JJ,Ducroix M,JP M .2008 .Azathioprine or methotrexate maintenance for ANCA-associated vasculitis. New Engl J Med, 10(26) : 2790-803.
Maritati F,Alberici F,Oliva E,Urban ML,Palmisano A,Santarsia F .2017 .Methotrexate versus cyclophosphamide for remission maintenance in ANCA-associated vasculitis: A randomised trial. PloS One, 0185880(10) : .
Jayne D,Rasmussen N,Andrassy K,Bacon P,Tervaert JWC,Dadoniene J .2003 .A randomised trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. New Engl J Med, 10(1) : 36-44.
Jayne D,Blockmans D,Luqmani R,Moiseev S,Ji B,Green Y .2019 .E cacy and safety of belimumab and azathioprine for maintenance of remission in antineutrophil cytoplasmic antibody-associated vasculitis: A randomised controlled study. Arthritis Rheumatol, 10(6) : 952-63.
Hiemstra TF,Walsh M,Mahr A,Savage CO,de Groot K,Harper L .2010 .Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: A randomised controlled trial. JAMA, 1658(21) : 2381-8.
Guillevin L,Pagnoux C,Karras A,Khouatra C,Aumaitre O,Cohen P .2014 .Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. New Engl J Med, 10(19) : 1771-80.
Hutton B,Salanti G,Caldwell DM,Chaimani A,Schmid CH,Cameron C .2015 .The PRISMA extension statement for reporting of systematic reviews incorporating network metaanalyses of health care interventions: Checklist and explanations. Ann Intern Med, 10(11) : 2385-84.
Higgins JP,Altman DG,Gotzsche PC,Moher D,Oxman AD .2011 .The Cochrane collaboration's tool for assessing risk of bias in randomised trials. BMJ, 10 : .
Wei A,Gu Z,Li J,Liu X,Wu X,Han Y .2016 .Clinical adverse e ects of endothelin receptor antagonists: Insights from the meta-analysis of 4894 patients from 24 randomised doubleblind placebo-controlled clinical trials. J Am Heart Assoc, 10(11) : .
Chaimani A,Higgins JP,Mavridis D,Spyridonos P,Salanti G .2013 .Graphical tools for network meta-analysis in STATA. PloS One, 0076654(10) : .
Wang YB,Cui YX,Song JN,Yang Q,Wang G. .2018 .E cacies of various surgical regimens in the treatment of renal calculi patients: A network meta-analysis in 25 enrolled controlled clinical trials. Kidney Blood Press Res, 43(4) : 1183-98.
. .. doi: 10, : .
Higgins JP,Jackson D,Barrett JK,Lu G,Ades AE,White IR .2012 .Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies. Res Synth Methods, 10(2) : 98-110.
White IR,Barrett JK,Jackson D,Higgins JP .2012 .Consistency and inconsistency in network meta-analysis: Model estimation using multivariate meta-regression. Res Synth Methods, 10(2) : 111-25.
Wan X,Wang W,Liu J,Tong T. Estimating .2014 .the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol, 10 : 1471.
Hozo SP,Djulbegovic B,Hozo I. Estimating .2005 .the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol, 10 : 1471.
Mbuagbaw L,Rochwerg B,Jaeschke R,Andsell DH,Alhazzani W,Thabane L .2017 .Approaches to interpreting and choosing the best treatments in network meta-analyses. Syst Rev, 10(1) : 79.
Ross C,Makhzoum JP,Pagnoux C. .2022 .Updates in ANCAassociated vasculitis. Eur J Rheumatol, 20248(3) : 153-66.
Sattui SE,Spiera RF .2019 .Treatment of antineutrophil cytoplasmic antibody-associated vasculitis: Is there still a role for cyclophosphamide?. Rheum Dis Clin North Am, 04(3) : 379-98.
Monti S,Brandolino F,Milanesi A,Xoxi B,Delvino P,Montecucco C .2021 .Novel therapies for ANCA-associated vasculitis. Curr Rheumatol Rep, 10(6) : 38.
Salvador F. .2020 .ANCA associated vasculitis. Eur J Intern Med, 01 : 18-28.
Lee YH,Song GG .2022 .Comparative e cacy and safety of rituximab, mycophenolate, methotrexate, and cyclophosphamide versus azathioprine as maintenance therapy in antineutrophil cytoplasmic antibody-associated vasculitis: A Bayesian network meta-analysis of randomised controlled trials. Int J Clin Pharmacol Ther, 10(2) : 97-105.
0

Citations

0

Downloads

60

Views